Population pharmacokinetic–pharmacodynamic model of elinzanetant based on integrated clinical phase I and II data

• Published in: CPT: pharmacometrics and systems pharmacology Vol. 13; no. 12; pp. 2137 - 2149
• Main Authors: Willmann, Stefan, Lloyd, Adam, Austin, Rupert, Joseph, Shiju, Solms, Alexander, Zhang, Yang, Schneider, Annika R. P., Frechen, Sebastian, Schultze‐Mosgau, Marcus‐Hillert
• Format: Journal Article
• Language: English
• Published: United States John Wiley & Sons, Inc 01.12.2024; John Wiley and Sons Inc; Wiley
• Subjects: Administration, Oral; Adult; Aged; Bioavailability; Biological Availability; Breast cancer; Clinical Trials, Phase I as Topic; Clinical Trials, Phase II as Topic; Datasets; Dose-Response Relationship, Drug; Drug dosages; Female; Females; Humans; Male; Menopause; Metabolites; Middle Aged; Models, Biological; Neurokinin-1 Receptor Antagonists - administration & dosage; Neurokinin-1 Receptor Antagonists - pharmacokinetics; Neurokinin-1 Receptor Antagonists - pharmacology; Pharmacodynamics; Pharmacokinetics; Plasma; Womens health; Young Adult
• ISSN: 2163-8306; 2163-8306
• DOI: 10.1002/psp4.13226

Elinzanetant is a potent and selective dual neurokin‐1 (NK‐1) and ‐3 (NK‐3) receptor antagonist that is currently developed for the treatment of women with moderate‐to‐severe vasomotor symptoms (VMS) associated with menopause. Here, we report the development of a population pharmacokinetic (popPK) model for elinzanetant and its principal metabolites based on an integrated dataset from 366 subjects (including 197 women with VMS) collected in 10 phase I or II studies. The pharmacokinetics of elinzanetant and its metabolites could be well described by the popPK model. Within the investigated dose range of 40–160 mg, the oral bioavailability of elinzanetant was dose independent and estimated to be 36.7%. The clearance of elinzanetant was estimated to be 7.26 L/h and the central and peripheral distribution volume were 23.7 and 168 L. No intrinsic or extrinsic influencing factors have been identified in the investigated population other than the effect of a high‐fat breakfast on the oral absorption of elinzanetant. The popPK model was then coupled to a pharmacodynamic model to predict occupancies of the NK‐1 and NK‐3 receptors. After repeated once‐daily administration of the anticipated therapeutic dose of 120 mg elinzanetant, the model‐predicted median receptor occupancies are >99% for NK‐1 and >94.8% for NK‐3 during day and night‐time, indicating sustained and near‐complete inhibition of both target receptors during the dosing interval.